Floatz logo

cd22 car-t

B-ALL

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

140 Active assets in the B-ALL cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

cd22 car-t is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell Lymphoma RecurrentDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →